Cited by 317Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Burstein, Harold J.·2020·New England Journal of Medicine

Open this paper in CoChat — free account

Abstract

ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.

Integrity signals

Registry

Crossref · 10.1056/nejmra1307118

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J. B., Kim, W., Cronin, M. T., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,597
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,054
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor–positive breast cancer: ATLAS, a randomised trial
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., Veer, L. J. V., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J., Brain, E. G. C., Causeret, S., Delorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 2,038
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R. G., Braybrooke, J. P., Davies, C., Taylor, C. W., McGale, P., Peto, R., Pritchard, K. I., Bergh, J. C. S., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,892
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,550
Gene-Expression Signatures in Breast Cancer
Sotiriou, C. P., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,506
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,280
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martín, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,056
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., Leeneer, K. D., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 853
Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A. I., Blohmer, J., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Bergh, J. C. S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60908-4 · Cited by 754
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Cuzick, J. M., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L. A., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 741
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Dowsett, M., Cuzick, J. M., Wale, C., Forbes, J., Mallon, E., Salter, J., Quinn, E., Dunbier, A. K., Baum, M., Buzdar, A. U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Genomic characterization of metastatic breast cancers
Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N. M., Piscuoglio, S., Carbuccia, N., Soria, J., Dien, A. T., Adnani, Y., Kamal, M. T., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 723
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 711
Self-citation
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less
Fisher, B., Bryant, J., Dignam, J. J., Wickerham, D. L., Mamounas, E. P., Fisher, E. R., Margolese, R. G., Nesbitt, L., Paik, S., Pisansky, T. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.101 · Cited by 668
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H. B., Gralow, J. R., Gelmon, K. A., Whelan, T. J., Strasser‐Weippl, K., Rubin, S. H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 655
Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
Ellis, M. J., Tao, Y., Luo, J. R., A’Hern, R., Evans, D. B., Bhatnagar, A. S., Ross, H. A. C., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 654
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., Watson, D., Geyer, C. E., Wickerham, D. L., & Wolmark, N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7610 · Cited by 613
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M. V., Panasci, L., Manikhas, A., Shparyk, Y. V., Cardona‐Huerta, S., Cheung, K., Philco, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 589
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904819 · Cited by 551
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Partridge, A. H., Hughes, M. E., Warner, E. T., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8013 · Cited by 495
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Spring, L. M., Wander, S. A., André, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 488
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Božović‐Spasojević, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C. P., & Piccart, M. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 465
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 447
Breast Cancer in Men
Giordano, S. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1707939 · Cited by 412
A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes
Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G. S., Kidd, J., Brown, K. L., Sharma, L., Saam, J. R., Lancaster, J. M., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 400
Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis
Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1897 · Cited by 396
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
Clark, G. M., Osborne, C. K., & McGuire, W. L. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.10.1102 · Cited by 391
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
Henry, N. L., Azzouz, F., Desta, Z., Li, L., Nguyen, A., Lemler, S. M., Hayden, J. A., Tarpinian, K., Yakim, E., Flockhart, D. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0261 · Cited by 388
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Barroso‐Sousa, R., Jain, E., Cohen, O., Kim, D., Buendia-Buendia, J. E., Winer, E. P., Lin, N., Tolaney, S. M., & Wagle, N. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.010 · Cited by 370
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Tung, N., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A. J., Balmañà, J., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 335
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
Swain, S. M., Jeong, J., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J. A., Vogel, V. G., Erban, J. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909638 · Cited by 331
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Küemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 325
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
Šestak, I., Buus, R., Cuzick, J. M., Dubsky, P. C., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D. C., Schnabel, C. A., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 320
Genomic Characterization of Primary Invasive Lobular Breast Cancer
Desmedt, C., Zoppoli, G. M., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D. N., Rothé, F., Vincent, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0334 · Cited by 316
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic‐Radisic, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O’Shaughnessy, J., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 232
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
Ferreira, A. R., Meglio, A. D., Pistilli, B., Gbenou, A. S., Mouhebb, M. E., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz298 · Cited by 231
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Alba, E., Calvo, L., Albanell, J., de la Haba-Rodríguez, J., Lanza, A. A., Chacón, J. I., Sánchez‐Rovira, P., Plazaola, A., García‐Asenjo, J. A. L., Bermejo, B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds132 · Cited by 229
BRCA1/2 testing: therapeutic implications for breast cancer management
Tung, N., & Garber, J. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0127-5 · Cited by 228
Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
Šestak, I., Dowsett, M., Zabaglo, L. A., López‐Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt244 · Cited by 226
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
Bartlett, J. M. S., Bayani, J., Marshall, A., Dunn, J., Campbell, A. M., Cunningham, C., Sobol, M. S., Hall, P. S., Poole, C. J., Cameron, D., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw050 · Cited by 216
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Blok, E. J., Kroep, J. R., Kranenbarg, E. M., Carpentier, M. D., Putter, H., Bosch, J., Maartense, E., van Leeuwen‐Stok, A. E., Liefers, G., Nortier, J. W. R., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 205
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger, O., Giobbie‐Hurder, A., Mallon, E., Gusterson, B. A., Viale, G., Winer, E. P., Thurlimann, B. J. K., Gelber, R. D., Colleoni, M. A., Ejlertsen, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8133 · Cited by 188
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard, J., Luo, W., Ribi, K., Colleoni, M. A., Burstein, H. J., Tondini, C. A., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00049-2 · Cited by 181
Self-citation
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F., Lévy, C., Mouret‐Reynier, M., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 174
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
Fribbens, C. V., García-Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 171
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Turner, N. C., Swift, C., Kilburn, L., Fribbens, C. V., Beaney, M., García-Murillas, I., Budzar, A. U., Robertson, J. F. R., Gradishar, W. J., Piccart, M. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0224 · Cited by 169
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., Chia, S., Brufsky, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30621-1 · Cited by 168
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial
Melisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155
Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer
Li, Y., Yang, D., Yin, X., Zhang, X., Huang, J., Wu, Y., Wang, M., Yi, Z., Li, H., Li, H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18160 · Cited by 152
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Kalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 152
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Pinotti, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01967 · Cited by 149
Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
Tevaarwerk, A. J., Wang, Μ., Zhao, F., Fetting, J. H., Cella, D. F., Wagner, L. I., Martino, S., Ingle, J. N., Sparano, J. A., Solin, L. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6993 · Cited by 147
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J. C. S., Chia, S., Bernard, P. S., Nielsen, T. O., Ellis, M. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds080 · Cited by 141
The changing role of ER in endocrine resistance
Nardone, A., Angelis, C. D., Trivedi, M. V., Osborne, C. K., & Schiff, R. (2015) · The Breast · doi:10.1016/j.breast.2015.07.015 · Cited by 138
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac, L., Keshaviah, A. P., Debled, M., Mouridsen, H. T., Forbes, J., Thurlimann, B. J. K., Paridaens, R., Monnier, A., Láng, I., Wardley, A. M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm001 · Cited by 136
Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors
Tang, G., Cuzick, J. M., Costantino, J. P., Dowsett, M., Forbes, J., Crager, M., Mamounas, E. P., Shak, S., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3714 · Cited by 135
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
Mamounas, E. P., Liu, Q., Paik, S., Baehner, F. L., Tang, G., Jeong, J., Kim, S. R., Butler, S. M., Jamshidian, F., Cherbavaz, D. B., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw259 · Cited by 129
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Ciruelos, E., Bellet, M., Pavesi, L., Lluch, A. M., Visini, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8675 · Cited by 127
Self-citation
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811714 · Cited by 126
Outcome of special types of luminal breast cancer
Colleoni, M. A., Rotmensz, N., Maisonneuve, P., Mastropasqua, M. G., Luini, A., Veronesi, P., Intra, M., Montagna, E., Cancello, G., Cardillo, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr461 · Cited by 123
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx
Wagner, L. I., Gray, R. J., Sparano, J. A., Whelan, T. J., Garcia, S. F., Yanez, B. R., Tevaarwerk, A. J., Carlos, R. C., Albain, K. S., Olson, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01866 · Cited by 112
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller, T., Giobbie‐Hurder, A., Colleoni, M. A., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00440 · Cited by 111
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale, G., Regan, M. M., Dell’Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G. M., Forbes, J., Paridaens, R., Colleoni, M. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq738 · Cited by 101
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Kashiwaba, M., Ohtani, S., Taira, N., Sakai, T., Hasegawa, Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4964-y · Cited by 101
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Prat, A., Galván, P., Jiménez, B., Buckingham, W., Jeiranian, H. A., Schaper, C., Vidal, M. J., Álvarez, M., Díaz, S., Ellis, C. E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0630 · Cited by 97
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
Palmieri, C., Cleator, S. J., Kilburn, L., Kim, S.-B., Ahn, S. H., Beresford, M. J., Gong, G., Mansi, J., Mallon, E., Reed, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3183-4 · Cited by 96
Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Bear, H. D., Wan, W., Robidoux, A., Rubin, P., Limentani, S. A., White, R. L., Granfortuna, J. M., Hopkins, J. O., Oldham, D. S., Rodriguez, A. A., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24610 · Cited by 96
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases
Hoefnagel, L. D. C., Moelans, C. B., Meijer, S. L., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., et al. (2012) · Cancer · doi:10.1002/cncr.27518 · Cited by 93
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer
Woodward, W. A., Barlow, W. E., Jagsi, R., Buchholz, T. A., Shak, S., Baehner, F. L., Whelan, T. J., Davidson, N. E., Ingle, J. N., King, T. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5559 · Cited by 78
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu, P. D., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Collins, L. C., Peppercorn, J. M., Schapira, L., Borges, V. F., Come, S. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01959 · Cited by 73
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
Levine, M. N., Julian, J. A., Bedard, P. L., Eisen, A. F., Trudeau, M., Higgins, B. P., Bordeleau, L. J., & Pritchard, K. I. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8503 · Cited by 71
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer
Albanell, J., Svedman, C., Gligorov, J., Holt, S., Bertelli, G., Blohmer, J., Rouzier, R., Lluch, A. M., & EIERMANN, W. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.027 · Cited by 71
Management of Aromatase Inhibitor–Induced Musculoskeletal Symptoms
Gupta, A., Henry, N. L., & Loprinzi, C. L. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00113 · Cited by 70
Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
Coates, A. S., Colleoni, M. A., & Goldhirsch, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7879 · Cited by 67
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
Tung, N., Robson, M. E., Ventz, S., Santa-Maria, C. A., Marcom, P. K., Nanda, R., Shah, P. D., Ballinger, T. J., Yang, E. S.-H., Melisko, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1002 · Cited by 60
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study
Noske, A., Möbus, V. J., Weber, K. E., Schmatloch, S., Weichert, W., Köhne, C., Solbach, C., Heppner, B. I., Steiger, K., Müller, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.010 · Cited by 48
Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy
Seah, D. S. E., Vaz-Luís, I., Macrae, E. R., Sohl, J. J., Litsas, G., Winer, E. P., Lin, N., & Burstein, H. J. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0008 · Cited by 47
Self-citation
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer
Dowsett, M., Lønning, P. E., & Davidson, N. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3728 · Cited by 38
Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial
Gnant, M., Steger, G. G., Greil, R., Fitzal, F., Mlineritsch, B., Manfreda, D., Tausch, C., Balić, M., Dubsky, P. C., Moik, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs3-01 · Cited by 37
Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk
Dowsett, M., & Turner, N. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01412 · Cited by 33
Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System
Weiss, A. C., King, T. A., Hunt, K. K., & Mittendorf, E. A. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2018.03.005 · Cited by 28
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
Veer, L. V. ‘., Yau, C. S. F., Yu, N., Benz, C. C., Nordenskjöld, B. A., Fornander, T., Stål, O., Esserman, L. J., & Lindström, L. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4428-9 · Cited by 19
Management of Hormone Deprivation Symptoms After Cancer
Faubion, S. S., Loprinzi, C. L., & Ruddy, K. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.009 · Cited by 14
Pharmacogenomics and Endocrine Therapy in Breast Cancer
Hayes, D. F., & Rae, J. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.03119 · Cited by 13

Research works printed but not linked: 2

Kalinsky K Barlow WE Meric-Bernstam F et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes hormone receptor positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOGS1007 (RxPONDER). Presented at the virtual San Antonio Breast Cancer Symposium December 8–11 2020. abstract.
Mayer EL Gnant M DeMichele A et al. PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Presented at the ESMO Virtual Congress September 20 2020. abstract. · DOI

Sorted by citations

Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A. K., Jemal, A., & Siegel, R. L. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,473
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W., Poortmans, P., Regan, M. M., Senn, H.-J., Winer, E. P., Gnant, M. I., Aebi, S. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 875
Self-citation
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658

See all 317

Authors: Burstein, H. J.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Burstein, Harold J.
ORCID: Burstein, Harold J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-12-24
Volume: 383
Issue: 26
Pages: 2557-2570
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1307118
OpenAlex: W3116128628
Cited by: 316
References: 106
Citations by year: 2026: 51 · 2025: 53 · 2024: 67 · 2023: 62 · 2022: 53 · 2021: 30
FWCI: 3.70
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: estrogen receptor-positive breast cancer, HER2-negative breast cancer, systemic therapy, antiestrogen therapy, breast cancer heterogeneity, progesterone receptor expression, tumor grade
MeSH terms: Breast Neoplasms, Female, Humans, Prognosis, Receptors, Estrogen, Chemotherapy, Adjuvant, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Neoadjuvant Therapy, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks